These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Extracorporeal Photopheresis and Its Use in Clinical Dermatology in Canada.
    Author: Lagacé F, Netchiporouk E, Turchin I, Gulliver W, Dutz J, Kirchhof MG, Popradi P, Gniadecki R, Lynde C, Litvinov IV.
    Journal: Skin Therapy Lett; 2022 Sep; 27(5):1-6. PubMed ID: 36469458.
    Abstract:
    Extracorporeal photopheresis (ECP) is an immunomodulatory therapy that has been used for over 35 years to treat numerous conditions. ECP was initially approved by the US FDA in 1988 for the treatment of Sézary syndrome, a leukemic form of cutaneous T-cell lymphoma (CTCL). Although CTCL remains the only FDA-approved indication, ECP has since been used off-label for numerous other conditions, including graft-versus-host disease (GvHD), systemic sclerosis, autoimmune bullous dermatoses, Crohn's disease, and prevention of solid organ transplant rejection. In Canada, ECP is mainly used to treat CTCL, acute and chronic GvHD, and in some instances systemic sclerosis. Herein, we review the current concepts regarding ECP mechanism of action, treatment considerations and protocols, and efficacy.
    [Abstract] [Full Text] [Related] [New Search]